- Investor's Business Daily•8 hours ago
Regeneron and Sanofi argue Amgen's patents covering LDL-buster Repatha are too broad.
- PR Newswire•14 hours agodeCODE Study Shows that Variants in the Sequence of the Genome that Contribute to Educational Attainment are Under Negative Selection
In a study published today, scientists at deCODE genetics use genomic and genealogical data from across the population of Iceland over many decades to show that people who carry sequence variations linked to higher levels of education have fewer children than average. As a result, variations in the sequence of the human genome correlated with more education are becoming rarer in the population over time - that is, they are under negative selection in an evolutionary sense. "These findings are an example of how we can use genomics to shed light on the evolutionary causes and consequences of observed social trends in modern human society," said Kari Stefansson, CEO of deCODE and one of the authors on the paper.
- Motley Fool•17 hours ago
Amgen has the dividends, while Celgene has the growth. Which biotech stock is the better pick for investors?
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Bid||153.80 x 100|
|Ask||155.50 x 100|
|Day's Range||153.53 - 156.12|
|52 Week Range||133.64 - 176.85|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||15.50|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|